title: Interaction of Ethambutol with human organic cation transporters of the SLC22 family indicates potential for drug-drug interactions during antituberculosis therapy.
abstract: According to the 2012 WHO global tuberculosis (TB) report (http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf), the death rate for tuberculosis was over 1.4 million patients in 2011, with ∼9 million new cases diagnosed. Moreover, the frequency of comorbidity with human immunodeficiency virus (HIV) and with diabetes is on the rise, increasing the risk of these patients for experiencing drug-drug interactions (DDIs) due to polypharmacy. Ethambutol is considered a first-line antituberculosis drug. Ethambutol is an organic cation at physiological pH, and its major metabolite, 2,2'-(ethylenediimino)dibutyric acid (EDA), is zwitterionic. Therefore, we assessed the effects of ethambutol and EDA on the function of human organic cation transporter 1 (hOCT1), hOCT2, and hOCT3 and that of EDA on organic anion transporter 1 (hOAT1) and hOAT3. Potent inhibition of hOCT1- and hOCT2-mediated transport by ethambutol (50% inhibitory concentration [IC50] = 92.6 ± 10.9 and 253.8 ± 90.8 μM, respectively) was observed. Ethambutol exhibited much weaker inhibition of hOCT3 (IC50 = 4.1 ± 1.6 mM); however, significant inhibition (>80%) was observed at physiologically relevant concentrations in the gastrointestinal (GI) tract after oral dosing. EDA failed to exhibit any inhibitory effects that warranted further investigation. DDI analysis indicated a strong potential for ethambutol interaction on hOCT1 expressed in enterocytes and hepatocytes and on hOCT3 in enterocytes, which would alter absorption, distribution, and excretion of coadministered cationic drugs, suggesting that in vivo pharmacokinetic studies are necessary to confirm drug safety and efficacy. In particular, TB patients with coexisting HIV or diabetes might experience significant DDIs in situations of coadministration of ethambutol and clinical therapeutics known to be hOCT1/hOCT3 substrates (e.g., lamivudine or metformin).
authors.affiliation: Department of Pharmaceutics, Virginia Commonwealth University, Richmond, Virginia, USA.
authors.forename: Xiaolei
authors.initials: X
authors.lastname: Pan
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Dirk
authors.initials: D
authors.lastname: Gründemann
authors.forename: Douglas H
authors.initials: DH
authors.lastname: Sweet
mesh_terms: D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology*; D001692:Biological Transport / Q000187:drug effects; D016466:CHO Cells; D003412:Cricetulus; D004347:Drug Interactions; D020895:Enterocytes / Q000187:drug effects; D004977:Ethambutol / Q000494:pharmacology*; D022781:Hepatocytes / Q000187:drug effects; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology; D008687:Metformin / Q000494:pharmacology; D027701:Organic Cation Transport Proteins / Q000378:metabolism*; D027702:Organic Cation Transporter 1 / Q000378:metabolism*
chemical_list: D000995:Antitubercular Agents; D027701:Organic Cation Transport Proteins; D027702:Organic Cation Transporter 1; D019259:Lamivudine; D004977:Ethambutol; D008687:Metformin
references.citation: IUBMB Life. 2002 Sep;54(3):129-35
references.pmid: 12489640
references.citation: Hepatology. 2002 Jul;36(1):164-72
references.pmid: 12085361
references.citation: Treat Guidel Med Lett. 2012 Mar;10(116):29-36; quiz 37-8
references.pmid: 22450707
references.citation: Toxicol Appl Pharmacol. 1981 Sep 15;60(2):163-75
references.pmid: 7197064
references.citation: Cancer Treat Rep. 1984 Jun;68(6):849-53
references.pmid: 6539649
references.citation: Biochem Pharmacol. 2012 Oct 15;84(8):1088-95
references.pmid: 22877817
references.citation: Ann N Y Acad Sci. 1966 Apr 20;135(2):711-25
references.pmid: 4287131
references.citation: Clin Invest Med. 1991 Oct;14(5):388-94
references.pmid: 1742916
references.citation: Antimicrob Agents Chemother. 1976 Jul;10(1):164-72
references.pmid: 984748
references.citation: Antimicrob Agents Chemother. 1999 Mar;43(3):568-72
references.pmid: 10049268
references.citation: N Z Med J. 1998 Nov 13;111(1077):428-30
references.pmid: 9861923
references.citation: J Clin Invest. 2007 May;117(5):1422-31
references.pmid: 17476361
references.citation: Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4001-5
references.pmid: 8633005
references.citation: Trop Med Int Health. 2012 Jul;17(7):877-83
references.pmid: 22574967
references.citation: Nat Rev Drug Discov. 2010 Mar;9(3):215-36
references.pmid: 20190787
references.citation: Cancer Lett. 1983 May;19(1):107-11
references.pmid: 6221790
references.citation: Br Med J. 1976 Nov 6;2(6044):1105-6
references.pmid: 990786
references.citation: Drug Metab Dispos. 2008 Aug;36(8):1616-23
references.pmid: 18490433
references.citation: N Engl J Med. 1972 Apr 6;286(14):761-2
references.pmid: 5025779
references.citation: Drug Metab Dispos. 2008 Nov;36(11):2299-306
references.pmid: 18710896
references.citation: Clin Pharmacol Ther. 2008 Feb;83(2):273-80
references.pmid: 17609683
references.citation: Toxicol Sci. 1999 Feb;47(2):181-6
references.pmid: 10220855
references.citation: Biochem Pharmacol. 1982 Jul 1;31(13):2243-6
references.pmid: 6889863
references.citation: J Pharmacol Exp Ther. 1980 Jun;213(3):551-6
references.pmid: 7193726
references.citation: PLoS Pathog. 2012 Feb;8(2):e1002464
references.pmid: 22363214
references.citation: Nature. 2002 May 23;417(6887):447-52
references.pmid: 12024214
references.citation: Int J Tuberc Lung Dis. 2004 Nov;8(11):1360-7
references.pmid: 15581206
references.citation: Future Microbiol. 2009 Jun;4(5):597-614
references.pmid: 19492969
references.citation: AAPS J. 2013 Jan;15(1):53-69
references.pmid: 23054972
references.citation: Biopharm Drug Dispos. 2010 Jan;31(1):1-71
references.pmid: 19953504
references.citation: Tuberculosis (Edinb). 2007 May;87(3):248-55
references.pmid: 17258938
references.citation: PLoS One. 2011;6(7):e22163
references.pmid: 21779389
references.citation: J Pharmacol Exp Ther. 2003 Feb;304(2):810-7
references.pmid: 12538837
references.citation: Clin Pharmacokinet. 1984 Nov-Dec;9(6):511-44
references.pmid: 6391781
references.citation: Drug Metab Pharmacokinet. 2013;28(3):220-8
references.pmid: 23229784
references.citation: Am J Pathol. 2005 Dec;167(6):1477-84
references.pmid: 16314463
references.citation: Nephron. 1991;59(4):679-80
references.pmid: 1766519
references.citation: Antimicrob Agents Chemother. 2011 Sep;55(9):4230-7
references.pmid: 21690284
references.citation: Pharm Res. 2005 Feb;22(2):255-9
references.pmid: 15783073
references.citation: Biochem Pharmacol. 2007 Aug 1;74(3):477-87
references.pmid: 17582384
references.citation: Antimicrob Agents Chemother. 2011 Feb;55(2):879-87
references.pmid: 21078936
references.citation: J Am Soc Nephrol. 2000 Mar;11(3):383-393
references.pmid: 10703662
references.citation: Life Sci. 1983 Feb 14;32(7):685-90
references.pmid: 6338333
references.citation: Mol Pharmacol. 2008 Jul;74(1):122-31
references.pmid: 18381565
references.citation: Pharmacol Rev. 1998 Sep;50(3):387-412
references.pmid: 9755288
references.citation: Pharm Res. 2007 Jul;24(7):1227-51
references.pmid: 17473959
references.citation: Infection. 2013 Apr;41(2):379-85
references.pmid: 22875535
references.citation: Nat Neurosci. 1998 Sep;1(5):349-51
references.pmid: 10196521
references.citation: Antimicrob Agents Chemother. 2012 Mar;56(3):1502-7
references.pmid: 22155817